Graves' Disease

MarketVue®: Graves’ Disease

The MarketVue®: Graves’ Disease market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Graves’ Disease report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Immunovant Inc.
• Novartis Pharmaceuticals
• AV7
• Worg Pharmaceuticals
• Crinetics
• Septerna

Key drugs mentioned:
• Levothyroxine
• Methimazole (Northyx, Tapazole)
• Rituximab
• Belimumab (Benlysta)
• Batoclimab / IMVT-1401
• Iscalimab / CFZ533
• K1-70
• WP1302
• VA-K-14
• ANTAG-3
• S37a

Key takeaways from the report:
Graves’ Disease (GD) is an autoimmune disease and the leading cause of overactive thyroid. For the last several decades, the GD treatment landscape has included three main options:
• Anti-thyroid drugs (methimazole and propylthiouracil)
• Radioiodine ablation
• Thyroidectomy
The majority of GD patients elect for anti-thyroid drugs (ATDs) as first-line because it is the only non-definitive treatment option and can also induce and sustain remission off therapy, although less than half of patients will successfully achieve this outcome. Patients who relapse can opt for another round of ATDs or choose a definitive option like radioiodine ablation or surgery – both of which irreversibly destroy the thyroid gland and require patients to take lifelong thyroid hormone replacement therapy. According to REACH Market Research’s MarketVue® assessment, endocrinologists are eager for novel, targeted therapeutics for GD that do not irreversibly destroy the thyroid gland.
Endocrinologist, U.S.— “Patients want a treatment, and we do too, that targets the source of the problem, which is the antibody to the TSH receptor, rather than treating the downstream consequences with some fairly extreme options.”
Despite high disease prevalence of GD (over 75,000 newly diagnosed cases per year in the US), the pipeline remains sparse with only a few biologics in early-stage development, including:
• Immunovant’s FcRn monoclonal antibody, batoclimab, which recently initiated a Phase 2 trial
• Anti-TSHR monoclonal antibodies, peptides, and antagonist small molecules that are in preclinical stages or early Phase 1 trials
Tyler Jakab, Analyst at REACH: “Graves’ patients hope for disease remission off ATD therapy, but relapse rates remain high. The introduction of another therapy may offer an additional opportunity for remission among those who relapse and are otherwise hesitant to undergo a definitive treatment like ablation or surgery.”

Please note: the online download version of this report is for a global site license.